TY - JOUR
T1 - Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients
AU - Jiralerspong, S.
AU - Kim, E. S.
AU - Dong, W.
AU - Feng, L.
AU - Hortobagyi, G. N.
AU - Giordano, S. H.
N1 - Funding Information:
This work was supported by the Nellie B. Connally Breast Cancer Research Fund; the American Society of Clinical Oncology [ASCO-Breast Cancer Research Foundation Young Investigator Award to SJ], the American Association for Cancer Research [AACR-Amgen Fellowship in Clinical/Translational Cancer Research to SJ], the Barbara Rattay Foundation [Barbara Rattay Advanced Scholar Award to SJ]; and by the NCI at the National Institutes of Health [K07CA109064 to SHG].
PY - 2013/10
Y1 - 2013/10
N2 - Background: To determine the relationship between obesity, diabetes, and survival in a large cohort of breast cancer patients receiving modern chemotherapy and endocrine therapy. Patients and methods: We identified 6342 patients with stage I-III breast cancer treated between 1996 and 2005. Patients were evaluated according to body mass index (BMI) category and diabetes status. Results: In a multivariate model adjusted for body mass index, diabetes, medical comorbidities, patient- and tumorrelated variables, and adjuvant therapies, relative to the normal weight, hazard ratios (HRs) for recurrence-free survival (RFS), overall survival (OS), and breast cancer-specific survival (BCSS) for the overweight were 1.18 [95% confidence interval (CI) 1.02-1.36], 1.20 (95% CI 1.00-1.42), and 1.21 (95% CI 0.98-1.48), respectively. HRs for RFS, OS, and BCSS for the obese were 1.13 (95% CI 0.98-1.31), 1.24 (95% CI 1.04-1.48), and 1.23 (95% CI 1.00-1.52), respectively. Subset analyses showed these differences were significant for the ER-positive, but not ER-negative or HER2-positive, groups. Relative to nondiabetics, HRs for diabetics for RFS, OS, and BCSS were 1.21 (95% CI 0.98-1.49), 1.39 (95% CI 1.10-1.77), and 1.04 (95% CI 0.75-1.45), respectively. Conclusions: In patients receiving modern adjuvant therapies, obesity has a negative impact on RFS, OS, and BCSS; and diabetes has a negative impact on RFS and OS. Control of both may be important to improving survival in obese and diabetic breast cancer patients.
AB - Background: To determine the relationship between obesity, diabetes, and survival in a large cohort of breast cancer patients receiving modern chemotherapy and endocrine therapy. Patients and methods: We identified 6342 patients with stage I-III breast cancer treated between 1996 and 2005. Patients were evaluated according to body mass index (BMI) category and diabetes status. Results: In a multivariate model adjusted for body mass index, diabetes, medical comorbidities, patient- and tumorrelated variables, and adjuvant therapies, relative to the normal weight, hazard ratios (HRs) for recurrence-free survival (RFS), overall survival (OS), and breast cancer-specific survival (BCSS) for the overweight were 1.18 [95% confidence interval (CI) 1.02-1.36], 1.20 (95% CI 1.00-1.42), and 1.21 (95% CI 0.98-1.48), respectively. HRs for RFS, OS, and BCSS for the obese were 1.13 (95% CI 0.98-1.31), 1.24 (95% CI 1.04-1.48), and 1.23 (95% CI 1.00-1.52), respectively. Subset analyses showed these differences were significant for the ER-positive, but not ER-negative or HER2-positive, groups. Relative to nondiabetics, HRs for diabetics for RFS, OS, and BCSS were 1.21 (95% CI 0.98-1.49), 1.39 (95% CI 1.10-1.77), and 1.04 (95% CI 0.75-1.45), respectively. Conclusions: In patients receiving modern adjuvant therapies, obesity has a negative impact on RFS, OS, and BCSS; and diabetes has a negative impact on RFS and OS. Control of both may be important to improving survival in obese and diabetic breast cancer patients.
KW - Body mass index
KW - Breast cancer
KW - Diabetes
KW - Obesity
KW - Prognosis
KW - Survival outcomes
UR - http://www.scopus.com/inward/record.url?scp=84884730076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884730076&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdt224
DO - 10.1093/annonc/mdt224
M3 - Article
C2 - 23793035
AN - SCOPUS:84884730076
SN - 0923-7534
VL - 24
SP - 2506
EP - 2514
JO - Annals of Oncology
JF - Annals of Oncology
IS - 10
ER -